BACKGROUND: Short-acting β-agonist (SABA) use is well established in predicting asthma events in adults. However, this predictive ability has yet to be established in a pediatric population together with an assessment of amount of use. OBJECTIVE: To identify the number of SABA canisters that best predicts future asthma-related exacerbations and the optimal length of time for measurement of SABA use in pediatric and adult asthma patients. METHODS: Asthma patients were identified from a Medicaid and a commercially insured database (January 1, 2004, through December 31, 2005, and January 1, 2004, through June 30, 2006, respectively). Following the date of first asthma medication, an assessment period (3, 6, or 12 months) was used to measure SABA use. Asthma-related exacerbations were identified in the subsequent 12-month period. Receiver operating characteristic curve analyses and logistic regression were used to select the critical values of SABA use and optimal assessment periods and to conduct incremental analysis, respectively. RESULTS: A total of 33,793 Medicaid and 101,437 commercial patients met the study criteria. Use of 3 or more SABA canisters during 12 months was identified in both pediatric Medicaid and commercial populations to best predict an increased risk of an asthma-related exacerbation. For adults, use of 2 or more SABA canisters was found as the critical value with shorter optimal assessment periods of 3 and 6 months. Each additional SABA canister resulted in an 8% to 14% and 14% to 18% increase in risk of an asthma-related exacerbation in children and adults, respectively. CONCLUSION: The study identified critical values of SABA use that predict future asthma events. Each additional SABA canister predicted increases in exacerbation risk in children and adults.
BACKGROUND: Short-acting β-agonist (SABA) use is well established in predicting asthma events in adults. However, this predictive ability has yet to be established in a pediatric population together with an assessment of amount of use. OBJECTIVE: To identify the number of SABA canisters that best predicts future asthma-related exacerbations and the optimal length of time for measurement of SABA use in pediatric and adult asthma patients. METHODS: Asthma patients were identified from a Medicaid and a commercially insured database (January 1, 2004, through December 31, 2005, and January 1, 2004, through June 30, 2006, respectively). Following the date of first asthma medication, an assessment period (3, 6, or 12 months) was used to measure SABA use. Asthma-related exacerbations were identified in the subsequent 12-month period. Receiver operating characteristic curve analyses and logistic regression were used to select the critical values of SABA use and optimal assessment periods and to conduct incremental analysis, respectively. RESULTS: A total of 33,793 Medicaid and 101,437 commercial patients met the study criteria. Use of 3 or more SABA canisters during 12 months was identified in both pediatric Medicaid and commercial populations to best predict an increased risk of an asthma-related exacerbation. For adults, use of 2 or more SABA canisters was found as the critical value with shorter optimal assessment periods of 3 and 6 months. Each additional SABA canister resulted in an 8% to 14% and 14% to 18% increase in risk of an asthma-related exacerbation in children and adults, respectively. CONCLUSION: The study identified critical values of SABA use that predict future asthma events. Each additional SABA canister predicted increases in exacerbation risk in children and adults.
Authors: Arlene M Butz; Jean Ogborn; Shawna Mudd; Jeromie Ballreich; Mona Tsoukleris; Joan Kub; Melissa Bellin; Mary Elizabeth Bollinger Journal: Ann Allergy Asthma Immunol Date: 2015-03-31 Impact factor: 6.347
Authors: Andrew Menzies-Gow; David J Jackson; Mona Al-Ahmad; Eugene R Bleecker; Francisco de Borja G Cosio Piqueras; Stephen Brunton; Giorgio Walter Canonica; Charles K N Chan; John Haughney; Steve Holmes; Janwillem Kocks; Tonya Winders Journal: Adv Ther Date: 2022-10-17 Impact factor: 4.070
Authors: Nicole M Wagner; Debra P Ritzwoller; Marsha A Raebel; Glenn K Goodrich; Peter J Cvietusa; Diane K King; Jo Ann Shoup; Bruce G Bender Journal: Transl Behav Med Date: 2021-04-07 Impact factor: 3.046
Authors: Sally A Hull; Shauna McKibben; Kate Homer; Stephanie Jc Taylor; Katy Pike; Chris Griffiths Journal: NPJ Prim Care Respir Med Date: 2016-08-18 Impact factor: 2.871
Authors: Gene Colice; Alison Chisholm; Alexandra L Dima; Helen K Reddel; Annie Burden; Richard J Martin; Guy Brusselle; Todor A Popov; Julie von Ziegenweidt; David B Price Journal: Pragmat Obs Res Date: 2018-08-10